Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 59

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 59
---
binding interactions that impacts patient safety could materially impact our ability to advance our product candidates into clinical
trials or to proceed to marketing approval and commercialization.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.

We face an inherent risk
of product liability as a result of the planned clinical testing of our product candidates and will face an even greater risk if we commercialize
any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise
unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects
in manufacturing, defects in design, packaging, a failure to warn of dangers inherent in the product, negligence, strict liability or
a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves
against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates.
Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability
claims may result in:

| ● | decreased demand for our                            
 product candidates or products that we may develop; |

| ● | injury to our reputation; |

| ● | withdrawal of clinical 
 trial participants;    |

| ● | initiation of investigations 
 by regulators;               |

| ● | costs to defend the related 
 litigation;                 |

| ● | a diversion of management’s 
 time and our resources;     |

| ● | substantial monetary awards        
 to trial participants or patients; |

| ● | product recalls, withdrawals                        
 or labeling, marketing or promotional restrictions; |

| ● | loss of revenue; |

| ● | exhaustion of any available          
 insurance and our capital resources; |

| ● | the inability to commercialize 
 any product candidate; and     |

| ● | a decline in our stock 
 price.                 |

Failure to obtain or retain
sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit
the commercialization of products we develop, alone or with corporate collaborators. Although we plan on purchasing clinical trial insurance,
such insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage.
We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not
covered by our insurance, and we may